PDSB PDS Biotechnology Corp: institutional ownership and insider trading
59 funds reported holding $8.65M of PDS Biotechnology Corp in their latest 13F filings; in Q2 2026 funds net bought $2.34M, with 13 new positions and 4 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
PDSB revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.75M, EPS -0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$7.35M, EPS -0.13
- Quarter ended Dec 31, 2025: revenue n/a, net income −$7.56M, EPS -0.13
- Quarter ended Sep 30, 2025: revenue n/a, net income −$9.01M, EPS -0.19
Famous investors holding PDSB
- Ken Griffin (Citadel Advisors): $307K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $222K, 0.0% of the portfolio
Largest institutional holders of PDSB
- VANGUARD GROUP INC — $1.50M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.50M
- Focus Partners Wealth — $566K
- Quantinno Capital Management LP — $566K
- BlackRock, Inc. (BLK) — $535K
- GEODE CAPITAL MANAGEMENT, LLC — $517K
- VANGUARD FIDUCIARY TRUST CO — $315K
- CITADEL ADVISORS LLC — $307K
- Militia Capital Management LLC — $292K
- Caption Management, LLC — $281K
Recent PDSB insider trades
- Feb 28, 2025: Freitag Gregory Gene bought 15,060 shares ($25.0K)
- Feb 28, 2025: Glover Stephen C. bought 15,061 shares ($25.0K)
5%+ owners
- Nant Capital, LLC: 19.9% (Schedule 13D, filed Sep 21, 2026)